Induction of apoptosis by HBI-8000 in adult T-cell leukemia/lymphoma is associated with activation of Bim and NLRP3

Cancer Science

Volumn 107, Issue 8, 2016, Pages 1124-1133

  Hasegawa, Hiroo ^a,b   Bissonnette, Reid P ^c   Gillings, Mireille ^c   Sasaki, Daisuke ^a   Taniguchi, Hiroaki ^a   Kitanosono, Hideaki ^a   Tsuruda, Kazuto ^a   Kosai, Kousuke ^b   Uno, Naoki ^b   Morinaga, Yoshitomo ^b   Imaizumi, Yoshitaka ^a   Miyazaki, Yasushi ^a,d   Yanagihara, Katsunori ^a,b  

^a NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c HUYA Bioscience International   (United States)

^d NAGASAKI UNIVERSITY   (Japan)

Author keywords

Adult T cell leukemia lymphoma; apoptosis; Bim; histone deacetylase inhibitors; NLRP3

Indexed keywords

BIM PROTEIN; CASPASE 3; CRYOPYRIN; HBI 8000; HISTONE DEACETYLASE INHIBITOR; LIPOCORTIN 5; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; T CELL LEUKEMIA; T-CELL LEUKEMIA CELL LINE;

EID: 84982113683     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12971     Document Type: Article

References (44)

1. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol 1991; 79: 428–37.
2. Tsukasaki K, Tobinai K. Biology and treatment of HTLV-1 associated T-cell lymphomas. Best Pract Res Clin Haematol. 2013; 26: 3–14.
3. Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014; 15: e517–26.
4. Yoshie O, Fujisawa R, Nakayama T et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 2002; 99: 1505–11.
5. Ishida T, Utsunomiya A, Iida S et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003; 9: 3625–34.
6. Ishida T, Joh T, Uike N et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30: 837–42.
7. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014; 13: 673–91.
8. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003; 63: 3637–45.
9. Hasegawa H, Yamada Y, Tsukasaki K et al. LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. Leukemia 2011; 25: 575–87.
10. Chen J, Zhang M, Ju W, Waldmann TA. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. Blood 2009; 113: 1287–93.
11. Pan D-S, Yang Q-J, Fu X et al. Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment. MedChemComm. 2014; 5: 1789–96.
12. Ning ZQ, Li ZB, Newman MJ et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol 2012; 69: 901–9.
13. Gong K, Xie J, Yi H, Li W. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J. 2012; 443: 735–46.
14. Yao Y, Zhou J, Wang L et al. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. PLoS ONE 2013; 8: e70522.
15. Wang H, Guo Y, Fu M et al. Antitumor activity of Chidamide in hepatocellular carcinoma cell lines. Mol Med Rep. 2012; 5: 1503–8.
16. Liu L, Chen B, Qin S et al. A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. Biochem Biophys Res Commun 2010; 392: 190–5.
17. Zhou Y, Pan DS, Shan S et al. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells. Biomed Pharmacother 2014; 68: 483–91.
18. Shi Y, Dong M, Hong X et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 2015; 26: 1766–71.
19. Kamihira S, Sugahara K, Tsuruda K et al. Proviral status of HTLV-1 integrated into the host genomic DNA of adult T-cell leukemia cells. Clin Lab Haematol 2005; 27: 235–41.
20. Maeda T, Yamada Y, Moriuchi R et al. Fas gene mutation in the progression of adult T cell leukemia. J Exp Med 1999; 189: 1063–71.
21. Hasegawa H, Yamada Y, Harasawa H et al. Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand. Br J Haematol 2005; 128: 253–65.
22. Hasegawa H, Yamada Y, Iha H et al. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells. Leukemia 2009; 23: 2090–101.
23. Sasaki D, Imaizumi Y, Hasegawa H et al. Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica 2011; 96: 712–9.
24. Taniguchi H, Hasegawa H, Sasaki D et al. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells. Cancer Sci 2014; 105: 1601–8.
25. Wong JC, Guo L, Peng Z et al. Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy. Bioorg Med Chem Lett 2011; 21: 110–6.
26. Ashkenazi A, Salvesen G. Regulated cell death: signaling and mechanisms. Annu Rev Cell Dev Biol 2014; 30: 337–56.
27. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621–63.
28. Bouillet P, Purton JF, Godfrey DI et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 2002; 415: 922–6.
29. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013; 13: 397–411.
30. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10: 417–26.
31. Nishioka C, Ikezoe T, Yang J et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. Leuk Res 2008; 32: 287–96.
32. Matsui H, Asou H, Inaba T. Cytokines direct the regulation of Bim mRNA stability by heat-shock cognate protein 70. Mol Cell 2007; 25: 99–112.
33. Akiyama T, Dass CR, Choong PF. Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther 2009; 8: 3173–80.
34. Bolden JE, Shi W, Jankowski K et al. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis 2013; 4: e519.
35. Muhleisen A, Giaisi M, Kohler R, Krammer PH, Li-Weber M. Tax contributes apoptosis resistance to HTLV-1-infected T cells via suppression of Bid and Bim expression. Cell Death Dis 2014; 5: e1575.
36. Tanaka-Nakanishi A, Yasunaga J, Takai K, Matsuoka M. HTLV-1 bZIP factor suppresses apoptosis by attenuating the function of FoxO3a and altering its localization. Cancer Res 2014; 74: 188–200.
37. Wei Q, Mu K, Li T et al. Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression. Lab Invest 2014; 94: 52–62.
38. Gram AM, Frenkel J, Ressing ME. Inflammasomes and viruses: cellular defence versus viral offence. J Gen Virol 2012; 93: 2063–75.
39. Dowling JK, O'Neill LA. Biochemical regulation of the inflammasome. Crit Rev Biochem Mol Biol 2012; 47: 424–43.
40. Haneklaus M, O'Neill LA, Coll RC. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr Opin Immunol 2013; 25: 40–5.
41. Allen IC, Scull MA, Moore CB et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 2009; 30: 556–65.
42. Doitsh G, Galloway NL, Geng X et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 2014; 505: 509–14.
43. Rayamajhi M, Zhang Y, Miao EA. Detection of pyroptosis by measuring released lactate dehydrogenase activity. Methods Mol Biol 2013; 1040: 85–90.
44. Sagulenko V, Thygesen SJ, Sester DP et al. AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. Cell Death Differ 2013; 20: 1149–60.